Health Condition 1: I220- Subsequent ST elevation (STEMI) myocardial infarction of anterior wall Health Condition 2: I221- Subsequent ST elevation (STEMI) myocardial infarction of inferior wall Health Condition 3: I228- Subsequent ST elevation (STEMI) myocardial infarction of other sites
Conditions
Interventions
Intervention1: Clinical Pharmacist Led Patient Education Plus Usual Cardiac Care: Hospitalized STEMI patients undergoing PCI will receive structured clinical pharmacist led education in addition to us
Sponsors
Sajan Francis P
Eligibility
Inclusion criteria
Inclusion criteria: Patients aged 18 years to 65 Years. Patients diagnosed with ST-Elevation Myocardial Infarction (STEMI) and admitted to the hospital for its management. Patients undergoing their first-ever Percutaneous Coronary Intervention (PCI) procedure as part of their STEMI treatment. Patients willing to participate in the study and provide informed consent. Patients or their caregivers who have access to a smartphone.
Exclusion criteria
Exclusion criteria: Patients with chronic conditions such as carcinoma or other severe chronic illnesses that may impact study participation. Patients who do not have access to a smartphone. Patients unwilling to participate in the study. Patients with cognitive impairment or any condition that prevents effective communication and participation. Patients with a history of prior PCI or coronary artery bypass grafting (CABG). If any patient developed restenosis soon after the PCI the sample will be sent to lab for testing P2Y12 to confirm the resistance towards the anti-platelet drugs, if any resistance patients will be removed from the study. Patient those who are not willing for biomarker assessment during follow-up. Patients who fail to attend any scheduled follow-up assessments, leading to incomplete data collection during the study period will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in medication adherence and clinical outcome rates among STEMI patients post-primary PCI, assessed by validated adherence measurement tools at specified follow-up intervalsTimepoint: 0,3,6,9,12 Months | — |
Secondary
| Measure | Time frame |
|---|---|
| NILTimepoint: NIL | — |
Countries
India
Contacts
Public ContactSajan Francis P
Yenepoya Pharmacy College and Research Center
Outcome results
None listed